These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Nguyen BH; Kuo J; Budiman A; Christie H; Ali S Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019 [TBL] [Abstract][Full Text] [Related]
6. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody. Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803 [No Abstract] [Full Text] [Related]
7. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy. Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313 [TBL] [Abstract][Full Text] [Related]
8. Myasthenia gravis exacerbation associated with pembrolizumab. Zhu J; Li Y Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533 [No Abstract] [Full Text] [Related]
9. Pembrolizumab-induced myasthenia gravis: A fatal case report. March KL; Samarin MJ; Sodhi A; Owens RE J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928 [TBL] [Abstract][Full Text] [Related]
11. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review. Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638 [TBL] [Abstract][Full Text] [Related]
12. [A case of myasthenia gravis and myositis induced by pembrolizumab]. Noda T; Kageyama H; Miura M; Tamura T; Ito H Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124 [TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909 [TBL] [Abstract][Full Text] [Related]
16. Acute localised exanthematous pustulosis secondary to pembrolizumab. Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194 [No Abstract] [Full Text] [Related]
17. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Lau KH; Kumar A; Yang IH; Nowak RJ Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302 [TBL] [Abstract][Full Text] [Related]
18. [Electromyography of eye muscles in myasthenia gravis]. Tietze K; Glatzel W Psychiatr Neurol Med Psychol (Leipz); 1980 Feb; 32(2):111-5. PubMed ID: 7394081 [TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma. Pottier C; El Habnouni C; Kervarrec T; Beltran S; Samimi M Ann Dermatol Venereol; 2022 Jun; 149(2):142-145. PubMed ID: 35190214 [No Abstract] [Full Text] [Related]
20. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report. Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]